Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
Alberto BorghettiAndrea GiacomelliVanni BorghiArturo CicculloAlex DusinaMassimiliano FabbianiStefano RusconiMaurizio ZazziCristina MussiniSimona Di GiambenedettoPublished in: Open forum infectious diseases (2021)
The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- human immunodeficiency virus
- end stage renal disease
- hiv infected
- clinical practice
- ejection fraction
- chronic kidney disease
- newly diagnosed
- hepatitis c virus
- prognostic factors
- peritoneal dialysis
- hiv aids
- randomized controlled trial
- hiv positive
- phase iii
- patient reported
- smoking cessation
- double blind
- chemotherapy induced